Stay updated on Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the nivolumab–vorolanib study in refractory thoracic tumors is displayed, including study details and results information. The record indicates that the study is completed and is no longer recruiting participants.
    Difference
    73%
    Check dated 2026-11-07T14:09:57.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2. The page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T14:49:43.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    A site-wide banner announces an NIH website transition and says some content may use “Super Intelligence” instead of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T14:21:44.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.1 to v3.7.2, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-17T14:22:46.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T14:23:10.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study details, and the rendered content includes standard error page elements (doctype, meta, header, footer) rather than the study information and documents that were previously displayed.
    Difference
    22%
    Check dated 2026-09-19T18:16:31.000Z thumbnail image

Stay in the know with updates to Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+Vorolanib Safety/Activity in Thoracic Tumors Clinical Trial page.